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Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an emerging pathogen with a devastating impact on organ transplant
recipients (OTRs). Data describing urinary tract infections (UTIs) due to CRKP, compared to extended-spectrum -lactamase
(ESBL)-producing and susceptible K. pneumoniae, are lacking. We conducted a retrospective cohort study comparing OTRs
with a first episode of UTI due to CRKP, ESBL-producing K. pneumoniae, or susceptible K. pneumoniae. We identified 108 indi-
viduals; 22 (20%) had UTIs due to CRKP, 22 (20%) due to ESBL-producing K. pneumoniae, and 64 (60%) due to susceptible K.
pneumoniae. Compared to susceptible K. pneumoniae (27%), patients with UTIs due to CRKP or ESBL-producing K. pneu-
moniae were more likely to have a >24-hour stay in the intensive care unit (ICU) before or after development of the UTI (64%
and 77%, respectively; P < 0.001). Among 105/108 hospitalized patients (97%), the median lengths of stay prior to UTI with
CRKP or ESBL-producing K. pneumoniae (7 and 8 days, respectively) were significantly longer than that for susceptible K. pneu-
moniae (1 day; P < 0.001). Clinical failure was observed for 8 patients (36%) with CRKP, 4 (18%) with ESBL-producing K. pneu-
moniae, and 9 (14%) with susceptible K. pneumoniae (P  0.073). Microbiological failure was seen for 10 patients (45%) with
CRKP, compared with 2 (9%) with ESBL-producing K. pneumoniae and 2 (3%) with susceptible K. pneumoniae (P < 0.001). In
multivariable logistic regression analyses, CRKP was associated with greater odds of microbiological failure (versus ESBL-pro-
ducing K. pneumoniae: odds ratio [OR], 9.36, 95% confidence interval [CI], 1.94 to 72.1; versus susceptible K. pneumoniae: OR,
31.4, 95% CI, 5.91 to 264). In conclusion, CRKP is associated with ICU admission, long length of stay, and microbiological fail-
ure among OTRs with UTIs. Greater numbers are needed to determine risk factors for infection and differences in meaningful
endpoints associated with carbapenem resistance.
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a seri-ous emerging global pathogen with very limited therapeutic
options. Its impact on organ transplant recipients (OTRs) in par-
ticular is potentially devastating, given their use of immunosup-
pression and the frequency of their exposure to the health care
system, where Klebsiella spp. cause approximately 8% of health
care-associated infections in the United States. Twenty-seven per-
cent of health care-associated infections are catheter-associated
urinary tract infections (UTIs) and, among facilities reporting
these to the National Healthcare Safety Network (NHSN), 20%
observed that at least one Klebsiella sp. was carbapenem resistant
(1). CRKP UTIs among OTRs present diagnostic and therapeutic
challenges, and data addressing these issues are lacking. In partic-
ular, data describing the clinical significance of CRKP UTIs, com-
pared to extended-spectrum -lactamase (ESBL)-producing and
susceptible K. pneumoniae UTIs, are needed to provide new in-
sights into the treatment and prevention of these complicated in-
fections. Herein we review first episodes of UTI due to CRKP,
ESBL-producing K. pneumoniae, or susceptible K. pneumoniae in
all OTRs, with the aim of comparing microbiological and clinical
outcomes.
MATERIALS AND METHODS
Cases. We identified cases of UTI diagnosed at Cleveland Clinic, a 1,400-
bed academic medical center in Cleveland, Ohio, between 2006 and 2012
through a retrospective review of microbiology reports and electronic
medical records of every OTR with positive urine culture results for K.
pneumoniae. Only the first episode of UTI following transplantation was
considered. A standardized case report form was used to collect data on
demographic characteristics, clinical features, treatments, and outcomes.
This study was approved by the Cleveland Clinic institutional review
board.
Definitions. UTIs were defined according to the Centers for Disease
Control and Prevention/NHSN surveillance definition (2). The date of
diagnosis was the date on which the urine culture was obtained. Relapse
was defined as the development of UTI with the same pathogen within 30
days after diagnosis of the initial episode. The time to adequate antibiotic
therapy was the number of days between the date on which the urine
culture was obtained and the date on which an appropriate agent with in
vitro activity was administered. Intensive care unit (ICU) admission was
defined by a stay of 24 h at any time during hospitalization, before or
after development of the UTI. A urinary catheter was considered present if
there was documentation of a catheter at the time the urine culture was
obtained. Predictors of the primary outcomes included age, sex, trans-
plant type, bacteremia, length of stay (LOS) prior to UTI, ICU admission
at any time during hospitalization, and the presence of a urinary catheter.
The primary outcomes were clinical failure and microbiological failure.
Clinical failure was defined as continued fever or urgency, frequency,
dysuria, suprapubic tenderness, or costovertebral angle pain or tender-
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ness 72 h after receiving adequate antimicrobial therapy. Microbiological
failure occurred if positive urine culture results of 105 CFU/ml of the
original organism were found 72 h after appropriate antibiotic treat-
ment (3).
Infections were categorized into 3 groups, i.e., CRKP, ESBL-produc-
ing K. pneumoniae, or susceptible K. pneumoniae, based on the results of
susceptibility testing performed using the automated Vitek 2 system (bio-
Mérieux, Inc., Durham, NC) supplemented by manual methods. Isolates
with ertapenem MICs of 4 g/ml and positive modified Hodge test
results were considered CRKP (4). ESBL production was determined by
the Vitek 2 test detection of reduction of growth in wells containing ceph-
alosporins with clavulanic acid, compared to wells with the cephalosporin
alone. Isolates with positive ESBL test results were reported as resistant to
penicillins, cephalosporins, and aztreonam regardless of the MICs. Fosfo-
mycin susceptibility was determined by the Etest method (bioMérieux,
Inc., Durham, NC) performed with Mueller-Hinton agar (BBL; Becton,
Dickinson). This methodology represented the workflow in the microbi-
ology laboratory and generated results incorporated by clinicians into the
care of patients in a real-world setting at our institution.
Statistical analyses. Descriptive statistics were computed, and differ-
ences in characteristics across groups were analyzed by the chi-square test,
analysis of variance techniques, and nonparametric median comparisons
as appropriate. Multivariable analyses for factors associated with micro-
biological failure and clinical failure were performed using stepwise mul-
tiple logistic regression analyses. The criterion for entering the model was
significance at the   0.20 level, while the criterion for remaining in the
model was significance at the   0.05 level. Odds ratios (ORs) and cor-
responding 95% confidence intervals (CIs) were calculated. Model fits
were assessed using the Hosmer-Lemeshow goodness-of-fit statistic. All
statistical tests were two-tailed and utilized a 5% significance level. Anal-
yses were performed using JMP Pro 10 (SAS Institute, Cary, NC).
RESULTS
We identified 108 individuals; 22 (20%) had UTIs due to CRKP,
22 (20%) due to ESBL-producing K. pneumoniae, and 64 (60%)
due to susceptible K. pneumoniae. There were 40 kidney-only
transplants (37%) and 68 transplants of other solid organs (63%).
The mean age was 53 years, and 42 patients (39%) were male.
Overall, the median time from transplantation to UTI was 185
days (interquartile range [IQR], 38 to 712 days). As shown in
Table 1, bacteremic UTI was found in 7 patients with CRKP
(32%), 4 with ESBL-producing K. pneumoniae (18%), and 8 with
susceptible K. pneumoniae (13%) (P  0.150). Compared to sus-
ceptible K. pneumoniae (27%), patients with UTIs due to CRKP or
ESBL-producing K. pneumoniae were more likely to have a 24-
hour stay in the ICU before or after development of the UTI (64%
and 77%, respectively; P  0.001). Patients with UTIs due to sus-
ceptible K. pneumoniae were significantly less likely to have a uri-
nary catheter. Relapse of UTI occurred for 7 patients with CRKP
(32%), 4 with ESBL-producing K. pneumoniae (18%), and 7 with
susceptible K. pneumoniae (11%) (P  0.075). Among 105/108
hospitalized patients (97%), the median LOS prior to UTI for
CRKP and ESBL-producing K. pneumoniae (7 and 8 days, respec-
tively) were significantly longer than that for susceptible K. pneu-
moniae (1 day; P  0.001). The mean time to adequate antibiotic
TABLE 1 Characteristics of 108 OTRs with a first episode of UTI due to CRKP, ESBL-producing K. pneumoniae, or susceptible K. pneumoniae at
Cleveland Clinic in 2006 to 2012








(n  108) P
Age (mean  SD) (yr) 56  10.3 56  10.9 51  12.8 53  12.1 0.104
Male (no. [%]) 16 (73) 12 (55) 14 (22) 42 (39) 0.001
Time to UTI (median [IQR]) (days) 66 (22–208) 90 (34–512) 306 (59–984) 185 (38–712) 0.004
Transplant type (no. [%])
Kidney 7 (32) 6 (27) 27 (42) 40 (37)
Liver 7 (32) 12 (55) 15 (23) 34 (31)
Heart 2 (9) 0 (0) 4 (6) 6 (6)
Lung 3 (14) 2 (9) 7 (11) 12 (11)
Pancreas 0 (0) 0 (0) 2 (3) 2 (2)
Intestine 0 (0) 1 (5) 0 (0) 1 (1)
Kidney-liver 3 (14) 1 (5) 4 (6) 8 (7)
Kidney-pancreas 0 (0) 0 (0) 4 (6) 4 (4)
Kidney-heart 0 (0) 0 (0) 1 (2) 1 (1)
Clinical features
Bacteremia (no. [%]) 7 (32) 4 (18) 8 (13) 19 (18) 0.150
ICU admission (no. [%]) 14 (64) 17 (77) 17 (27) 48 (44) 0.001
Urinary catheter (no. [%]) 6 (27) 6 (27) 6 (9) 18 (17) 0.049
Relapse (no. [%]) 7 (32) 4 (18) 7 (11) 18 (17) 0.075
LOS prior to UTI (median [IQR]) (days) 7 (2–26) 8 (1–14) 1 (1–4) 2 (1–11) 0.001
Time to adequate antibiotics (mean  SD) (days) 2.73  2.1 1.36  1.1 1.31  1.9 1.61  1.9 0.006
Outcome (no. [%])
Clinical failure 8 (36) 4 (18) 9 (14) 21 (19) 0.073
Microbiological failure 10 (45) 2 (9) 2 (3) 14 (13) 0.001
All-cause death during hospitalization 4 (18) 4 (18) 1 (2) 9 (8) NS
a UTI, urinary tract infection; CRKP, carbapenem-resistant Klebsiella pneumoniae; ESBL, extended-spectrum -lactamase; SD, standard deviation; IQR, interquartile range; ICU,
intensive care unit; LOS, length of stay; NS, nonsignificant.
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therapy for CRKP (2.73 days) was significantly longer than those
for ESBL-producing K. pneumoniae or susceptible K. pneumoniae
(1.36 and 1.31 days, respectively; P  0.006).
Clinical failure was observed for 8 patients with CRKP (36%),
compared with 4 patients with ESBL-producing K. pneumoniae
(18%) and 9 patients with susceptible K. pneumoniae (14%) (P 
0.073). Microbiological failure was seen for 10 patients with CRKP
(45%), compared with 2 patients with ESBL-producing K. pneu-
moniae (9%) and 2 patients with susceptible K. pneumoniae (3%)
(P  0.001). The all-cause mortality rate during hospitalization
was 8% (9/108 patients). There were 4 deaths among patients with
CRKP and 4 among those with ESBL-producing K. pneumoniae.
In multivariable logistic regression analyses controlling for age,
sex, ICU admission, and transplant type, UTI caused by CRKP was
independently associated with greater odds of microbiological
failure (versus ESBL-producing K. pneumoniae: OR, 9.36 [95%
CI, 1.94 to 72.1]; versus susceptible K. pneumoniae: OR, 31.4 [95%
CI, 5.91 to 264]). Controlling for age, sex, ICU admission, and
urinary catheters, there were greater odds of clinical failure asso-
ciated with CRKP, but that finding did not reach statistical signif-
icance (versus ESBL-producing K. pneumoniae: OR, 2.26 [95% CI,
0.57 to 10.2]; versus susceptible K. pneumoniae: OR, 2.17 [95% CI,
0.61 to 7.53]).
With regard to treatment, considering only OTRs with UTIs
due to CRKP, 10 patients (45%) received an antibiotic regimen
containing colistin, 14 (64%) tigecycline, 1 (5%) a carbapenem, 6
(27%) an aminoglycoside, and 10 (45%) fosfomycin (Table 2).
Fourteen patients (64%) received combination antibiotic therapy
with at least 2 different classes of drugs. Notably, both clinical and
microbiological responses occurred for 3/14 patients (21%)
treated with tigecycline, 4/10 (40%) treated with colistin, 3/6
(50%) treated with aminoglycosides, and 5/10 (50%) treated with
fosfomycin. Generally, too few patients received any specific agent
to permit meaningful comparisons among drugs. Therefore, no
individual agent could be shown to be associated with the primary
outcomes in any of the multiple models evaluated (data not
shown).
DISCUSSION
To our knowledge, the present study is the largest detailed clinical
characterization and comparison of OTRs with UTIs due to
CRKP, ESBL-producing K. pneumoniae, or susceptible K. pneu-
moniae. We observed that UTIs caused by CRKP were associated
with greater odds of microbiological failure. We documented that
UTIs due to CRKP or ESBL-producing K. pneumoniae occurred
significantly earlier after transplantation than those due to suscep-
tible K. pneumoniae and were associated with a urinary catheter at
diagnosis, a 24-hour stay in the ICU either before or after devel-
opment of the UTI, and longer LOS prior to the UTI. These data
support the idea that, during the study period, CRKP was largely a
nosocomial pathogen. We further observed a trend toward an
increased likelihood of patients with CRKP experiencing relapse
within 30 days and continued fever or urgency, frequency, dys-
uria, suprapubic tenderness, or costovertebral angle pain or ten-
derness 72 h after receiving adequate antimicrobial therapy. The
mean time to initiation of that therapy was significantly longer for
CRKP.
UTI occurs more frequently in OTRs than in the nontransplant
population. For example, UTI, estimated to be associated with
approximately 44 to 47% of all infectious complications (5), is the
most common infection following kidney transplantation, but
published studies of UTI due to CRKP in OTRs are lacking. Sim-






OutcomeaColistin Tigecycline Carbapenem Aminoglycoside Fosfomycin
1b Heart 14 7 Clin and micro failure
2 Heart 30 Clin failure
3b Kidney 7 3 3 Clin and micro failure
4 Kidney 7 Response
5 Kidney 10 7 Response
6 Kidney 16 12 Response
7 Kidney 24 35 20 Clin and micro failure
8 Kidney 3 21 8 Micro failure
9 Kidney 4 120 10 Clin and micro failure
10 Liver 14 14 Micro failure
11b Liver 40 40 Clin failure
12b Liver 9 Clin failure
13 Liver 8 Micro failure
14 Liver 14 Response
15 Liver 26 7 Micro failure
16 Liver 6 Response
17 Liver and kidney 35 Micro failure
18 Liver and kidney 3 7 Response
19 Liver and kidney 14 7 Response
20 Lung 12 42 14 Response
21 Lung 3 Response
22 Lung 50 18 Clin and micro failure
a Clin, clinical; micro, microbiological.
b Death during hospitalization.
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kins and colleagues compared 9 kidney transplant recipients with
UTIs due to CRKP and 34 with carbapenem-susceptible K. pneu-
moniae (6). They observed a trend toward more bacteremia
among cases of CRKP, as well as a significantly higher mortality
rate at 6.5 months. Unfortunately, other investigations into CRKP
among OTRs excluded UTIs (7–10). Still others included both
OTRs and nontransplant patients but focused on a particular
therapy (11), bacteremia (12, 13), or factors associated with the
development of UTIs among patients with asymptomatic bacteri-
uria (14). Extrapolating from data for nontransplant patients is
problematic. It has been shown that, among mostly (81%) non-
transplant patients with UTIs due to CRKP, microbiological fail-
ure occurred in only 5 cases (24%) and bacteremia in 3 (14%)
(15). In contrast, we observed microbiological failure for 45% of
OTRs and bacteremic UTI due to CRKP for 32%. In addition, it
was shown that aminoglycosides were associated with clearance of
CRKP bacteriuria among nontransplant patients (16), but our
data demonstrated that 3/6 aminoglycoside-exposed OTRs (50%)
experienced microbiological failure. We hypothesize that immu-
nosuppressive medication enhances the importance of early active
antimicrobial therapy and accounts in part for the increased rates
of microbiological failure and bacteremia.
Our results are generally in agreement with the other very lim-
ited published studies. In Brazil, Argentina, and Israel, 12 OTRs
with UTIs due to CRKP have been described, 6 (50%) of whom
were bacteremic (17–19). Mortality rates ranged from 0 to 33%.
Finally, in a recent study of patients from the United States, there
were 11 OTRs with UTIs due to CRKP (14). While detailed clinical
characterizations were not provided, multivariate logistic regres-
sion analyses identified solid organ transplantation as indepen-
dently associated with UTI among all patients with CRKP bacte-
riuria (OR, 4.50 [95% CI, 1.39 to 14.52]).
In the present study, we report an additional 22 OTRs with
UTIs due to CRKP, with ESBL-producing K. pneumoniae and sus-
ceptible K. pneumoniae for comparison. As shown, many features
of UTIs due to ESBL-producing K. pneumoniae were similar to
those for CRKP; however, important differences emerged, partic-
ularly in the increased odds of microbiological failure associated
with CRKP. Failure to include ESBL-producing K. pneumoniae
would have placed the findings in an improper context, and the
results would have been much less informative. Although our
study provides some advantages, the observational design is lim-
ited by unmeasured confounders, such as the presence of ureteral
stents and confounding by indication. Therefore, some of our
observations should be interpreted cautiously. These data reflect
the biases of the clinicians at our institution. For example, provid-
ers more often repeated urine cultures for OTRs with UTIs due to
CRKP or ESBL-producing K. pneumoniae, which could bias the
results with regard to microbiological failure, in comparison to
susceptible K. pneumoniae. Finally, ESBL-producing K. pneu-
moniae and carbapenem resistance were defined phenotypically.
During the study period, testing for K. pneumoniae carbapen-
emase (KPC) production through detection of blaKPC was not
performed; however, subsequent PCR testing of the isolates with
positive results from the modified Hodge test revealed the over-
whelming majority to be blaKPC positive. While the phenotypic
definitions may be somewhat limited, results reflect the informa-
tion available to providers caring for these patients in a real-world
setting. Therefore, our data incorporating these definitions re-
main largely informative and relevant.
In conclusion, CRKP is associated with microbiological failure
among OTRs with UTIs and may be an important predictor of
clinical outcomes. There are few therapeutic options for CRKP,
and use of the available agents is limited by the parenteral route of
administration and toxicity, particularly among patients with re-
cent or ongoing organ failure syndromes, which are frequently
encountered among OTRs. This underscores the importance of
infection prevention. Additional studies with OTRs, with greater
patient numbers and an emphasis on determining modifiable risk
factors for the development of infection, are needed. These will
permit discovery of significant differences in clinically meaningful
endpoints associated with carbapenem resistance, which would be
invaluable to clinicians caring for OTRs.
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